Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of VV-14300 (Adeno-associated Virus Vector-mediated Glucokinase) in Adults With Long-Standing Type 1 Diabetes and Suboptimal Glycemic Control Using an Automated Insulin Delivery (AID) System

NCT07831798 is registered in ClinicalTrials.gov with Kriya Therapeutics, Inc. as lead sponsor.

NCT NCT07831798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07831798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of VV-14300 (Adeno-associated Virus Vector-mediated Glucokinase) in Adults With Long-Standing Type 1 Diabetes and Suboptimal Glycemic Control Using an Automated Insulin Delivery (AID) System
Lead sponsor
Kriya Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
November 30, 2028
Enrollment
29 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus